Enanta Pharmaceuticals Inc (ENTA) 34.78 $ENTA
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014
Business Wire - Mon May 12, 6:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal second quarter ended March 31, 2014.
Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel
Business Wire - Mon May 12, 6:15AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel. Mr. Gardiner has over 25 years of experience as outside general counsel advising private and public biotechnology companies.
Chelsea Therapeutics International Ltd. (CHTP) Looks Strong as Stock Shoots up 31.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:44AM CDT
Chelsea Therapeutics International Ltd. (CHTP) was a big mover last session, as the company saw its shares soar 31.6% on the day.
ARIAD's Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 11:00AM CDT
ARIAD Pharmaceuticals Inc. (ARIA) reported narrower-than-expected loss in the first quarter of 2014.
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Thu May 08, 5:15AM CDT
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date([1])
Enanta and AbbVie submits MAA to EMA for all-oral, interferon-free Hepatitis C regimen containing ABT-450
M2 - Thu May 08, 4:25AM CDT
Research and development biotechnology company Enanta Pharmaceuticals Inc (NASDAQ:ENTA), announced on Thursday that a Marketing Authorization Applications (MAA) has been submitted to the European Medicines Agency (EMA) seeking approval for the investigational, all-oral, interferon-free regimen for the treatment of adult patients infected with chronic genotype 1 (GT1) hepatitis C virus (HCV), by AbbVie, Enanta's collaboration partner for protease inhibitor ABT-450.
Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
Business Wire - Thu May 08, 1:03AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie, Enanta's collaboration partner for ABT-450, has submitted Marketing Authorization Applications (MAA) to the European Medicines Agency (EMA) seeking approval for its investigational, all-oral, interferon-free regimen for the treatment of adult patients infected with chronic genotype 1 (GT1) hepatitis C virus (HCV).
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
VIVUS Inc. (VVUS) in Focus: Stock Rises 7.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:44AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rally over 7% on the day.
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:44AM CDT
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Sequenom Inc. (SQNM) in Focus: Stock Rallies 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:44AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rally nearly 9.00% on the day.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:21AM CDT
Endo International plc (ENDP) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:17AM CDT
Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy?
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference
Business Wire - Wed Apr 30, 7:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present on Wednesday, May 7, 2014, at 4:50 p.m. ET during the 39th Annual Deutsche Bank Securities Healthcare Conference in Boston. The presentation format will be conducted as a fireside chat, or interview format and will be webcast live.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014
Business Wire - Mon May 12, 6:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today reported financial results for its fiscal second quarter ended March 31, 2014.
Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel
Business Wire - Mon May 12, 6:15AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced the appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel. Mr. Gardiner has over 25 years of experience as outside general counsel advising private and public biotechnology companies.
Chelsea Therapeutics International Ltd. (CHTP) Looks Strong as Stock Shoots up 31.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 09, 7:44AM CDT
Chelsea Therapeutics International Ltd. (CHTP) was a big mover last session, as the company saw its shares soar 31.6% on the day.
ARIAD's Q1 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 11:00AM CDT
ARIAD Pharmaceuticals Inc. (ARIA) reported narrower-than-expected loss in the first quarter of 2014.
AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C
PR Newswire Europe - Thu May 08, 5:15AM CDT
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date([1])
Enanta and AbbVie submits MAA to EMA for all-oral, interferon-free Hepatitis C regimen containing ABT-450
M2 - Thu May 08, 4:25AM CDT
Research and development biotechnology company Enanta Pharmaceuticals Inc (NASDAQ:ENTA), announced on Thursday that a Marketing Authorization Applications (MAA) has been submitted to the European Medicines Agency (EMA) seeking approval for the investigational, all-oral, interferon-free regimen for the treatment of adult patients infected with chronic genotype 1 (GT1) hepatitis C virus (HCV), by AbbVie, Enanta's collaboration partner for protease inhibitor ABT-450.
Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450
Business Wire - Thu May 08, 1:03AM CDT
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie, Enanta's collaboration partner for ABT-450, has submitted Marketing Authorization Applications (MAA) to the European Medicines Agency (EMA) seeking approval for its investigational, all-oral, interferon-free regimen for the treatment of adult patients infected with chronic genotype 1 (GT1) hepatitis C virus (HCV).
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
VIVUS Inc. (VVUS) in Focus: Stock Rises 7.23% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed May 07, 7:44AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rally over 7% on the day.
Wider-than-Expected Loss at Auxilium - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:20AM CDT
Auxilium Pharmaceuticals, Inc. (AUXL) reported first quarter 2014 loss (including stock-based compensation expense) of 47 cents per share.
Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue May 06, 7:44AM CDT
Endocyte, Inc. (ECYT) was a big mover last session, as the company saw its shares rally nearly 6% on the day.
Sequenom Inc. (SQNM) in Focus: Stock Rallies 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 05, 7:44AM CDT
Sequenom Inc. (SQNM) was a big mover last session, as the company saw its shares rally nearly 9.00% on the day.
2 Health Care Stocks to Watch: Enanta Pharmaceuticals, Inc. and PDLI BioPharma, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri May 02, 5:24PM CDT
Bargain hunters have largely stayed away from health-care stocks over the last year and for good reason. Specifically, this group of stocks has generally soared to record high price-to-earnings ratios ever since 2012, making them some of the most...
Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 8:21AM CDT
Endo International plc (ENDP) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri May 02, 7:44AM CDT
Merrimack Pharmaceuticals, Inc. (MACK) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day
Strength Seen in Avanir Pharmaceuticals, Inc. (AVNR) as Stock Shoots up 45.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 7:44AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) was a big mover last session, as the company saw its shares surge a whopping 45.6% on the day.
Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 01, 6:17AM CDT
Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy?
Auxilium Pharma Cuts Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 4:20PM CDT
Auxilium Pharma lowered its guidance for 2014 and cut its revenue guidance by $70 million to $380 million - $420 million.
Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference
Business Wire - Wed Apr 30, 7:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present on Wednesday, May 7, 2014, at 4:50 p.m. ET during the 39th Annual Deutsche Bank Securities Healthcare Conference in Boston. The presentation format will be conducted as a fireside chat, or interview format and will be webcast live.
